Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs

被引:414
作者
Jinno, J
Kamada, N
Miyake, M
Yamada, K
Mukai, T
Odomi, M
Toguchi, H
Liversidge, GG
Higaki, K
Kimura, T [1 ]
机构
[1] Okayama Univ, Fac Pharmaceut Sci, Dept Pharmaceut, Okayama 7008530, Japan
[2] Otsuka Pharmaceut Co Ltd, Tokushima 7710182, Japan
[3] Elan Drug Delivery Inc, King Of Prussia, PA 19406 USA
关键词
dissolution; bioavailability; particle size reduction; food effect; NanoCrystal; cilostazol;
D O I
10.1016/j.jconrel.2005.11.013
中图分类号
O6 [化学];
学科分类号
0703 [化学];
摘要
The purpose of the present study was to investigate the effects of particle size on the dissolution and oral absorption of cilostazol. Three types of suspensions having different particle size distributions were prepared of the hammer-milled, the jet-milled cilostazol crystals and the NanoCrystal (R) spray-dried powder of cilostazol. In vitro dissolution rate of cilostazol was significantly increased by reducing the particle size. The dissolution curves of the cilostazol suspensions were in good agreement with the simulation based on the Noyes-Whitney equation. The bioavailability of cilostazol after oral administration to dogs was increased with reducing the particle size. While positive food effect on the absorption was observed for the suspensions made of the hammer-milled and the jet-milled crystals, no significant food effect was found for the suspension made of the NanoCrystal (R) cilostazol spray-dried powder. These results could be qualitatively predicted from the in vitro dissolution data using the bio-relevant media, FaSSIF and FeSSIF. In conclusion, the NanoCrystal (R) technology is found to be efficient to improve the oral bioavailability of cilostazol and to avoid the food effect on the absorption. (c) 2005 Elsevier B.V All rights reserved.
引用
收藏
页码:56 / 64
页数:9
相关论文
共 33 条
[1]
ABDOU HM, 1990, REMINGTONS PHARM SCI, P589
[2]
AKIYAMA H, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1124
[3]
AKIYAMA H, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1133
[4]
A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[5]
Beebe HG, 2001, AM J CARDIOL, V87, p14D
[6]
Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics [J].
Bramer, SL ;
Forbes, WP .
CLINICAL PHARMACOKINETICS, 1999, 37 (Suppl 2) :13-23
[7]
Dawson DL, 2001, AM J CARDIOL, V87, p19D
[8]
MIXING-TANK MODEL FOR PREDICTING DISSOLUTION RATE CONTROL OF ORAL ABSORPTION [J].
DRESSMAN, JB ;
FLEISHER, D .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1986, 75 (02) :109-116
[9]
In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs [J].
Dressman, JB ;
Reppas, C .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 11 :S73-S80
[10]
Dissolution testing as a prognostic tool for oral drug absorption: Immediate release dosage forms [J].
Dressman, JB ;
Amidon, GL ;
Reppas, C ;
Shah, VP .
PHARMACEUTICAL RESEARCH, 1998, 15 (01) :11-22